ImmunityBio, Inc. — Investor Relations & Filings

ImmunityBio, Inc. is a commercial-stage biotechnology company developing next-generation immunotherapies and vaccines designed to strengthen a patient's own immune system. The company's approach focuses on orchestrating both the innate (natural killer cells) and adaptive (T cells) immune systems to combat cancer and infectious diseases. Its key platforms include the IL-15 superagonist Anktiva® (N-803), engineered natural killer (NK) cell therapies, and adenovirus-vectored vaccines. These therapies are being investigated and applied across a range of difficult-to-treat cancers, such as bladder, lung, and pancreatic cancers, as well as infectious diseases like HIV. The company's goal is to create durable, complete responses by treating the host's immune system rather than just the disease.